Recombinant AAV vector encoding human VEGF165 enhances wound healing

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Wound Healing Research

Background:

• Difficult-to-heal wounds, often seen in metabolic disorders or infections, pose significant clinical challenges.
• Enhancing new blood vessel formation (neo-angiogenesis) is a key therapeutic strategy for improving wound repair.
• Adeno-associated virus (AAV) vectors are being explored for targeted gene delivery in therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of AAV-mediated gene therapy for wound healing.
• To investigate the role of vascular endothelial growth factor-A (VEGF-A) in accelerating wound repair.
• To assess the potential of VEGF gene transfer as a novel treatment for wound healing disorders.

Main Methods:

• Utilized adeno-associated virus (AAV) vectors to deliver the gene for vascular endothelial growth factor-A (VEGF-A) isoform 165.
• Administered VEGF165 gene therapy to full-thickness excisional wounds in a rat model.
• Employed gene marker studies for efficient gene transfer assessment and histological examination for tissue remodeling analysis.

Main Results:

• AAV vectors demonstrated high efficiency and sustained gene transfer to rat skin, specifically targeting the panniculus carnosus.
• VEGF165 gene delivery significantly induced neo-angiogenesis at the wound site.
• Treated wounds exhibited accelerated epidermal and dermal remodeling, reduced healing time, and formation of new, larger blood vessels.

Conclusions:

• VEGF gene transfer via AAV vectors is a potent stimulator of neo-angiogenesis, crucial for wound healing.
• This gene therapy approach shows significant promise for treating disorders characterized by impaired wound healing.
• The findings highlight the therapeutic potential of targeting VEGF pathways for enhanced tissue regeneration.